Could You Qualify for a Personalized Cancer Vaccine?

Personalized cancer vaccines -- also called neoantigen vaccines -- are a new class of immunotherapy designed to target the unique genetic mutations in an individual patient's tumor. Unlike traditional treatments that attack all rapidly dividing cells, these vaccines train the patient's own immune system to recognize and destroy cancer cells with surgical precision.

While most neoantigen vaccines are still in clinical trials (Moderna/Merck's mRNA-4157 is in Phase 3 for melanoma), patients who don't qualify for a trial may still gain access through the FDA's Expanded Access program -- sometimes called "compassionate use." This regulatory pathway allows patients with serious or life-threatening conditions to receive investigational treatments outside of a clinical trial, provided their physician files an Investigational New Drug (IND) application.

Eligibility depends on several factors: cancer type, stage, prior treatment history, genomic sequencing status, and overall health. This free assessment tool walks you through the key criteria that expanded access programs and clinical trials typically evaluate. It takes approximately 2 minutes and provides a personalized summary of your potential eligibility along with recommended next steps.